Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Medchemexpress LLC NRX-0492 | 2416130-57-7 | C43H51N11O6 | 100 MG
Supplier: Medchemexpress LLC HY153357100MG
NRX-0492 is an orally active PROTAC-class BTK degrader that catalyzes BTK ubiquitination and proteasome degradation. It inhibits B cell receptor (BCR) mediated signaling, transcription programs, and chemokine secretion, demonstrating antitumor effects against chronic lymphocytic leukemia.
- Catalyzes BTK ubiquitination and proteasome degradation
- Inhibits B cell receptor (BCR) mediated signaling
- Inhibits transcription programs and chemokine secretion
- Demonstrates antitumor effects against chronic lymphocytic leukemia
- Shows high-affinity binding to wild-type and C481S/T474I mutant BTK
- Induces BTK degradation in CLL cells from blood and spleen in vivo
- Reduces proportion of Ki67+/CD69+ cells in vivo
- Decreases splenic tumor burden in CLL patient-derived xenografts
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
Spot an opportunity for improvement?